Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0ZRDFG
ADC Name	Brentuximab-PNUEDAGly5
Synonyms	Brentuximab PNU EDA Gly5; cAc10-PNUEDAGly5; cAc10 PNU EDA Gly5 Click to Show/Hide
Organization	NBE Therapeutics AG
Drug Status	Investigative
Indication	In total 1 Indication(s) Anaplastic large cell lymphoma [ICD11:2A90] Investigative
Drug-to-Antibody Ratio	4
Structure
	3D MOL	2D MOL
Antibody Name	Brentuximab		Antibody Info
Antigen Name	Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)		Antigen Info
Payload Name	PNU-159682		Payload Info
Therapeutic Target	DNA topoisomerase 2-alpha (TOP2A)		Target Info
Linker Name	LPETG-Gly5-EDA		Linker Info
Conjugate Type	Random conjugation through nucleophilic lysines.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Effective Concentration (EC50)	4.8	ng/mL	SK-BR-3 cells	Breast adenocarcinoma
Half Maximal Effective Concentration (EC50)	11	ng/mL	T-47D cells	Invasive breast carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.80 ng/mL	High HER2 expression (HER2 +++)
Method Description	For this, cells were plated on 96 well plates in 100 ul DMEM/10% FCS at adensity of 10⁴ cells per well and assays were performed.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11.00 ng/mL	Low HER2 expression (HER2 +)
Method Description	For this, cells were plated on 96 well plates in 100 ul DMEM/10% FCS at adensity of 10⁴ cells per well and assays were performed.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553

References

Ref 1	Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof; 2017-10-19.